Tianjin Med J ›› 2016, Vol. 44 ›› Issue (1): 121-123.doi: 10.11958/58840

• Review • Previous Articles     Next Articles

The research progress of interleukin 7 receptor in the development of lymphocytes and pathogenesis of multiple sclerosis

CAI Shijiao, LI Yuhao△   

  1. Key Laboratory of Tumor Microenviroment and Neurovascular Regulation, Nankai University School of Medicine,
    Tianjin 300071, China
  • Received:2015-04-24 Revised:2015-08-11 Published:2016-01-15 Online:2016-01-15
  • Contact: △Corresponding Author E-mail: liyuhao@nankai.edu.cn E-mail:liyuhao@nankai.edu.cn
  • Supported by:
    国家自然科学基金资助项目 (81301080); 天津市应用基础与前沿研究计划 (15JCYBJC24400); 教育部留学回国启动基金([2012]1707)

Abstract: △Corresponding Author E-mail: liyuhao@nankai.edu.cn Abstract: Interleukin 7 receptor (IL7R) is a transmembrane receptor that belongs to the type Ⅰ cytokine receptor fami⁃ ly. It consists of the cytokine-specific α-chain (IL7Rα, CD127) and the shared common cytokine γ-chain (γc, CD132). IL-7R is expressed in various cell types, including lymphoid precursor cells, pro-B cells, T cells, thymocytes, dendritic cells, myeloid cells and monocytes. Under physiological conditions, IL7R is a vital cytokine for development and survival of T and B cells. IL7R plays a key role in the pathogenesis of multiple sclerosis (MS). Single nucleotide polymorphisms (SNPs) in the gene encoding IL7Rα have emerged through genetic studies of MS patients. In experimental autoimmune encephalomy⁃ elitis (EAE) mouse model of MS, treatment with neutralizing anti-IL7Rα antibody results in significant improvement of EAE. Therefore, IL7R may serve as a novel target for MS therapies.

Key words: receptors, interleukin-7, lymphocytes, multiple sclerosis, review